Terms: = Kidney tumors AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132 AND Treatment
7 results:
1. FXR1 facilitates axitinib resistance in clear cell renal cell carcinoma via regulating keap1/Nrf2 signaling pathway.
Huang H; Zhang J; Jiang P; Xu X; Huang F; Zhao B; Wang X; Zhou L
Anticancer Drugs; 2023 Feb; 34(2):248-256. PubMed ID: 36730618
[TBL] [Abstract] [Full Text] [Related]
2. Catalytic activity tunable ceria nanoparticles prevent chemotherapy-induced acute kidney injury without interference with chemotherapeutics.
Weng Q; Sun H; Fang C; Xia F; Liao H; Lee J; Wang J; Xie A; Ren J; Guo X; Li F; Yang B; Ling D
Nat Commun; 2021 Mar; 12(1):1436. PubMed ID: 33664241
[TBL] [Abstract] [Full Text] [Related]
3. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.
Ooi A
Semin Cancer Biol; 2020 Apr; 61():158-166. PubMed ID: 31689495
[TBL] [Abstract] [Full Text] [Related]
4. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel kidney Injury Biomarkers in Patients Receiving Cisplatin.
Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant C; Bowles DW; George B; Wen X; Aleksunes LM; Joy MS
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640195
[TBL] [Abstract] [Full Text] [Related]
5. keap1/Nrf2 pathway in kidney cancer: frequent methylation of keap1 gene promoter in clear renal cell carcinoma.
Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
[TBL] [Abstract] [Full Text] [Related]
6. New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.
Srinivasan R; Ricketts CJ; Sourbier C; Linehan WM
Clin Cancer Res; 2015 Jan; 21(1):10-7. PubMed ID: 25564569
[TBL] [Abstract] [Full Text] [Related]
7. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.
Wang YY; Yang YX; Zhe H; He ZX; Zhou SF
Drug Des Devel Ther; 2014; 8():2075-88. PubMed ID: 25364233
[TBL] [Abstract] [Full Text] [Related]
